Peter Anton, MD is a professor of medicine within the Vatche and Tamar Manoukian Division of Digestive Diseases and a member of the UCLA AIDS Institute. He is director of the UCLA CFAR Mucosal Immunology Research Laboratory (MICL), director of the UCLA Center for HIV Prevention Research (CPR), and past co-director of the Center for Inflammatory Bowel Disease at UCLA.
Dr. Anton graduated magna cum laude from Harvard University in 1977 and received his MD from Case Western Reserve University in 1983. He did fellowship work at the Cholera Hospital, ICDDR, in Bangladesh in 1983 and a year fellowship in pathology in 1981 in Cleveland's Institute of Pathology. He performed his internship and residency in internal medicine at Bringham and Women's Hospital in Boston Massachusetts. Dr. Anton began in his work at UCLA in 1986 with a gastroenterology fellowship and has been on faculty since 1989.
Dr. Anton's research focuses on the degree of mucosal inflammation and altered co-receptor expression associated with HIV infection and associated therapeutic interventions, the potential use of the mucosa as a route of HIV immunization with various HIV vaccine candidates as well as microbicides for HIV mucosal prevention, investigating the interaction of HSV and HIV in mucosal pathogenesis and efforts to clarify the role of compartments in HIV pathogenesis.
He has been PI on over 30 clinical trials including two Phase I HIV vaccine trials and two Phase I anti-HIV topical microbicide trials. He recently completed research as PI of the NIH IPCP U19 award "Microbicide Development Program" (MDP), with national/international sub-study sites, focusing on a developmental pipeline for rectal microbicides. These rectal microbicide efforts have continued with both the Clinical Trials Project within the second IPCP U19 Combination HIV Antiretroviral Rectal Microbicide (CHARM) which has six exploratory pre-Phase I microbicide trials and JHU's DREAM project. His research has expanded into delayed-release vaginal drug delivery and IM/injectable drug delivery with Oak Crest Institute of Sciences' U19 and Northwestern University's UM1 SLAP-HIV.
Dr. Anton is active in several NIH-sponsored national HIV networks including the AIDS Clinical Trial Group (ACTG), HIV Vaccine Trials Network (HVTN), HIV Clinical Pharmacology Quality Assurance Program Advisory Board (CPQA AB), HIV Prevention Trials Network (HPTN), HIV/AIDS Network Coordination (HANC), the Microbicide Trials Network (MTN) and the HVTN Mucosal Immunology Focus Group (HVTN MIG).
Francisco Javier Ibarrondo, PhD, associate researcher, received his PhD in biochemistry from Basque Country University (Spain), going on to do postdoctoral work at the University Paris-Sud (Paris), University of Southern California, and at UCLA. He held the position of assistant researcher at UCLA from 2004 to 2006. In 2010 and 2011 he spent two years as researcher at the Foundation irsiCaixa-HIVACAT in Barcelona (Spain), where he participated in international efforts to develop an HIV vaccine candidate under the direction of Dr. Christian Brander. Returning to UCLA in 2012 as an associate researcher in Dr. Peter Anton's laboratory, his current research focuses on the role of B cells in gut-associated lymphoid issue on HIV-1 infection and aging.